Type 1 (T1) and type 2 (T2) diabetes mellitus (DM) are the most commonly recognized disease states characterized by hyperglycemia. However, diabetes compromises many disorders with hyperglycemia as a common feature. Other forms of diabetes include gestational diabetes, neonatal diabetes, cystic fibrosis-related diabetes, latent autoimmune diabetes in adults, and maturity-onset diabetes of the young (MODY). MODY affects pediatric patients and accounts for 2-5% of all diabetes cases (Timsit, Bellanné-Chantelot, Dubois-Laforgue, & Velho, 2005) . Accurate diagnosis is imperative as it impacts treatment, complication surveillance, family screening and genetic counseling. Limited awareness of MODY, its characteristics, and diagnostic methods is an obstacle to proper diagnosis and treatment. This article provides an overview of MODY and a framework for identifying potential cases.
MODY Overview
MODY is a genetic form of diabetes that usually presents after puberty. It is frequently misdiagnosed as T1 or T2 DM. A brief review of T1 and T2 DM is needed to highlight MODY's unique characteristics. T1 DM occurs from autoimmune destruction of the pancreatic beta cells resulting in absolute insulin deficiency and complete dependence on exogenous insulin (Kleinberger & Pollin, 2015) . T2 DM develops as a result of insulin resistance, a disorder in which the cells don't use insulin properly (Kleinberger & Pollin, 2015) . Treatment for T2 DM typically consists of lifestyle changes and oral anti-diabetic agents, although some may require insulin therapy due to beta cell exhaustion. There are many different forms of MODY and depending upon the affected gene, treatment may include oral sulfonylureas, insulin therapy, or no treatment at all.
Individuals with MODY may or may not present with typical symptoms of hyperglycemia such as polyuria, polydipsia, polyphagia and weight loss. They do not generally suffer from diabetic ketoacidosis (DKA) as is common in T1 DM. Laboratory evaluation reveals negative pancreatic autoantibodies for T1 DM, thereby raising suspicion for a diagnosis of T2 DM. However, signs that are common in children with T2 DM -overweight, acanthosis nigricans, and elevations in fasting serum insulin -are usually absent in children with MODY. In short, affected individuals present with a perplexing picture of hyperglycemia that is not consistent with T1 or T2 DM. As their clinical course progresses, unusually low insulin requirements are often observed beyond the "honeymoon" period seen in the early phase of T1 DM. A summary of clinical features that should raise suspicion for MODY is found in the Box.
Unlike T1 and T2 DM, MODY is a group of monogenic disorders. Monogenic diseases appear as the result of one defect in a single gene that is present in all cells of the body. Humans have two copies of each gene, one inherited from each parent. MODY is dominantly inherited and thus family history usually reveals diabetes in two or more consecutive generations of either the maternal or paternal pedigree.
Patients with features suspicious for a diagnosis of MODY require genetic testing for definitive diagnosis. Targeted next-generation sequencing (NGS) is a newer method of gene analysis that allows for sensitive, quicker, and more cost effective examination of many known MODY genes concurrently (Szopa et al., 2015) .
Common MODY Types
Mutations in at least 13 genes are known to result in MODY (Leslie, Palmer, Schloot, & Lernmark, 2016) . The gene defects result in disordered glucose sensing and insulin secretion resulting in hyperglycemia.
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• Endogenous insulin production beyond "honeymoon" period.
• T2 DM diagnosis in a young individual not significantly overweight or without signs of insulin resistance.
• Diabetes in two or more consecutive generations
There are varying degrees of microvascular and macrovascular complications based on MODY type. The Table 1 compares T1 DM, T2 DM, and four common MODY subtypes.
Although mutations in 13 genes may result in MODY, four mutations compromise the majority of all cases. The most common MODY gene mutations are found in hepatocyte nuclear factor 4 alpha (HNF4A-MODY 1), glucokinase (GCK-MODY 2), and hepatocyte nuclear factor 1 alpha (HNF1A-MODY 3) (McDonald & Ellard, 2013) . Combined defects in these three genes constitute approximately 80-85% of all MODY cases. Defects in hepatocyte nuclear factor 1 beta (HNF1B-MODY 5) accounts for about another 1% of MODY occurrences.
MODY due to mutations in genes such as PDX, NEUROD1, and INS are less frequent. It is important to note that novel mutations continue to occur and it is believed that many MODY-related genes are likely not yet identified (Anik, Catli, Abaci, & Böber, 2015) .
Case Study
S.D. is a 12-year-old Caucasian female who presented for a wellchild visit. Her BMI was 22.2 kg/m 2 (85th to 90th percentile). She had no symptoms of polyuria, polydipsia or weight loss. Routine urinalysis revealed glucosuria and small ketones. Random blood sugar was 177 mg/dL. Hemoglobin A 1c was 7.9% (normal b5.7%). Past medical history was non-contributory. Family history was notable for mother with T1 DM diagnosed at age 16 and maintained on insulin therapy. S.D. was started on insulin therapy. However, laboratory studies showed negative autoimmune markers for T1 DM and a normal fasting serum insulin level. She had no clinical signs of insulin resistance. Hemoglobin A 1c was 6% on small doses of insulin. Genetic testing for MODY was performed and S.D. was found to have a disease-causing mutation in the HNF1A gene (MODY 3). Insulin was discontinued and an oral sulfonylurea was started. Hemoglobin A1c remained in the 6-7% range on this regimen. Mother was tested and found to be positive for the same mutation and thus had carried an incorrect diagnosis of T1 DM since adolescence.
Conclusions
An estimated 95% of MODY cases are misdiagnosed as T1 or T2 DM (Kleinberger & Pollin, 2015) . A correct diagnosis can translate to more precise and less invasive treatment, cost savings, and improvements in patient satisfaction and quality of life. Accurate MODY diagnosis additionally allows for appropriate genetic counseling and identification and screening of vulnerable family members. Studies have shown a correlation between early treatment of MODY 3 with sulfonylureas and a decrease in incidence of micro-and macrovascular complication rates (Bacon et al., 2016) . Nurses are in a unique position to identify children with undiagnosed MODY. Improved awareness of MODY, its corresponding features, proper diagnostic approaches and recommended treatment represents an incredible opportunity to improve patient care. Anik et al., 2015; McDonald & Ellard, 2013; Timsit et al., 2005. 
